Dolutegravir treatment response by baseline viral load and NRTI backbone in treatment-naı̈ve HIV-infected individuals

Methods We analysed response rates and time to virologic failure by NRTI backbone and baseline viral load in the pivotal DTG-naive studies. SPRING-2 randomized participants to DTG 50 mg QD or RAL 400 mg BID, each in combination with investigator-selected NRTIs (TDF/FTC or ABC/3TC). SINGLE randomised participants to DTG 50 mg ABC/3TC QD or TDF/FTC/EFV (Atripla) QD. In SPRING-2, changes in serum creatinine were examined by INI and NRTI backbone.